<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="My EndNote Library-Converted.enl" path="/Users/mcowley/OneDrive - Childrens Cancer Institute/EndNote/My EndNote Library-Converted.enl">My EndNote Library-Converted.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>4043</rec-number><foreign-keys><key app="EN" db-id="asv5v5waft9zeless5z5t0vnrw9expvwste0">4043</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nair, R</style></author><author><style face="normal" font="default" size="100%">Roden, D L</style></author><author><style face="normal" font="default" size="100%">Teo, W S</style></author><author><style face="normal" font="default" size="100%">McFarland, A</style></author><author><style face="normal" font="default" size="100%">Junankar, S</style></author><author><style face="normal" font="default" size="100%">Ye, S</style></author><author><style face="normal" font="default" size="100%">Nguyen, A</style></author><author><style face="normal" font="default" size="100%">Yang, J</style></author><author><style face="normal" font="default" size="100%">Nikolic, I</style></author><author><style face="normal" font="default" size="100%">Hui, M</style></author><author><style face="normal" font="default" size="100%">Morey, A</style></author><author><style face="normal" font="default" size="100%">Shah, J</style></author><author><style face="normal" font="default" size="100%">Pfefferle, A D</style></author><author><style face="normal" font="default" size="100%">Usary, J</style></author><author><style face="normal" font="default" size="100%">Selinger, C</style></author><author><style face="normal" font="default" size="100%">Baker, L A</style></author><author><style face="normal" font="default" size="100%">Armstrong, N</style></author><author><style face="normal" font="default" size="100%">Cowley, M J</style></author><author><style face="normal" font="default" size="100%">Naylor, M J</style></author><author><style face="normal" font="default" size="100%">Ormandy, C J</style></author><author><style face="normal" font="default" size="100%">Lakhani, S R</style></author><author><style face="normal" font="default" size="100%">Herschkowitz, J I</style></author><author><style face="normal" font="default" size="100%">Perou, C M</style></author><author><style face="normal" font="default" size="100%">Kaplan, W</style></author><author><style face="normal" font="default" size="100%">Oâ€™Toole, S A</style></author><author><style face="normal" font="default" size="100%">Swarbrick, A</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cancer Research Division, The Kinghorn Cancer Centre and Cancer Research Program Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.</style></title><secondary-title><style face="normal" font="default" size="100%">Oncogene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Oncogene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3992-4002</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">30</style></number><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 24</style></date></pub-dates></dates><accession-num><style face="normal" font="default" size="100%">24056965</style></accession-num><abstract><style face="normal" font="default" size="100%">The HER2 (ERBB2) and MYC genes are commonly amplified in breast cancer, yet little is known about their molecular and clinical interaction. Using a novel chimeric mammary transgenic approach and in vitro models, we demonstrate markedly increased self-renewal and tumour-propagating capability of cells transformed with Her2 and c-Myc. Coexpression of both oncoproteins in cultured cells led to the activation of a c-Myc transcriptional signature and acquisition of a self-renewing phenotype independent of an epithelial-mesenchymal transition programme or regulation of conventional cancer stem cell markers. Instead, Her2 and c-Myc cooperated to induce the expression of lipoprotein lipase, which was required for proliferation and self-renewal in vitro. HER2 and MYC were frequently coamplified in breast cancer, associated with aggressive clinical behaviour and poor outcome. Lastly, we show that in HER2(+) breast cancer patients receiving adjuvant chemotherapy (but not targeted anti-Her2 therapy), MYC amplification is associated with a poor outcome. These findings demonstrate the importance of molecular and cellular context in oncogenic transformation and acquisition of a malignant stem-like phenotype and have diagnostic and therapeutic consequences for the clinical management of HER2(+) breast cancer.</style></abstract><label><style face="normal" font="default" size="100%">r07146</style></label><urls><related-urls><url><style face="normal" font="default" size="100%">http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;amp;id=24056965&amp;amp;retmode=ref&amp;amp;cmd=prlinks</style></url></related-urls><pdf-urls><url>file://localhost/Users/mcowley/OneDrive%20-%20Childrens%20Cancer%20Institute/Papers/Nair2014.pdf</url></pdf-urls></urls><custom3><style face="normal" font="default" size="100%">papers2://publication/uuid/6F97CF59-EBC9-4007-AC0E-73DC747F4904</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/onc.2013.368</style></electronic-resource-num><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="My EndNote Library-Converted.enl" path="/Users/mcowley/OneDrive - Childrens Cancer Institute/EndNote/My EndNote Library-Converted.enl">My EndNote Library-Converted.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>4427</rec-number><foreign-keys><key app="EN" db-id="asv5v5waft9zeless5z5t0vnrw9expvwste0">4427</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rius, R.</style></author><author><style face="normal" font="default" size="100%">Riley, L. G.</style></author><author><style face="normal" font="default" size="100%">Guo, Y.</style></author><author><style face="normal" font="default" size="100%">Menezes, M.</style></author><author><style face="normal" font="default" size="100%">Compton, A. G.</style></author><author><style face="normal" font="default" size="100%">Van Bergen, N. J.</style></author><author><style face="normal" font="default" size="100%">Gayevskiy, V.</style></author><author><style face="normal" font="default" size="100%">Cowley, M. J.</style></author><author><style face="normal" font="default" size="100%">Cummings, B. B.</style></author><author><style face="normal" font="default" size="100%">Adams, L.</style></author><author><style face="normal" font="default" size="100%">Ellaway, C.</style></author><author><style face="normal" font="default" size="100%">Thorburn, D. R.</style></author><author><style face="normal" font="default" size="100%">Hakonarson, H.</style></author><author><style face="normal" font="default" size="100%">Christodoulou, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Murdoch Children&apos;s Research Institute, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia.&#xD;Kids Research, The Children&apos;s Hospital at Westmead, Sydney, NSW, Australia; Discipline of Child &amp; Adolescent Health, Sydney Medical School, University of Sydney, Sydney, Australia.&#xD;Center for Applied Genomics, Children&apos;s Hospital of Philadelphia, Philadelphia, USA.&#xD;Kids Research, The Children&apos;s Hospital at Westmead, Sydney, NSW, Australia.&#xD;Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia.&#xD;Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia; St Vincent&apos;s Clinical School, UNSW Sydney, Sydney, Australia; Children&apos;s Cancer Institute, Kensington, Australia.&#xD;Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, USA.&#xD;Western Sydney Genetics Program, Children&apos;s Hospital at Westmead, Sydney, NSW, Australia.&#xD;Discipline of Child &amp; Adolescent Health, Sydney Medical School, University of Sydney, Sydney, Australia; Western Sydney Genetics Program, Children&apos;s Hospital at Westmead, Sydney, NSW, Australia.&#xD;Murdoch Children&apos;s Research Institute, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia. Electronic address: john.christodoulou@mcri.edu.au.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cryptic intronic NBAS variant reveals the genetic basis of recurrent liver failure in a child</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Genet Metab</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mol Genet Metab</style></full-title></periodical><pages><style face="normal" font="default" size="100%">77-82</style></pages><volume><style face="normal" font="default" size="100%">126</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2018/12/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style face="normal" font="default" size="100%">*Genetic Variation</style></keyword><keyword><style face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Introns</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Failure, Acute/diagnosis/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasm Proteins/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Whole Genome Sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">*Deep-intronic</style></keyword><keyword><style face="normal" font="default" size="100%">*Liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">*Pseudo-exon</style></keyword><keyword><style face="normal" font="default" size="100%">*Whole Genome Sequencing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1096-7206 (Electronic)&#xD;1096-7192 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">30558828</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In almost half of patients with acute liver failure the cause is unknown, making targeted treatment and decisions about liver transplantation a challenge. Monogenic disorders may contribute to a significant proportion of these undiagnosed patients, and so the incorporation of technologies such as next generation sequencing (NGS) in the clinic could aid in providing a definitive diagnosis. However, this technology may present a major challenge in interpretation of sequence variants, particularly those in non-coding regions. RESULTS: In this report we describe a case of Infantile liver failure syndrome 2 (ILFS2; MIM 616483) due to novel bi-allelic variants in the NBAS gene. A missense variant NM_015909.3(NBAS):c.2617C&gt;T, NP_056993.2(NBAS):p.(Arg873Trp) was identified by whole genome sequencing (WGS). By combining WGS and reverse transcription-polymerase chain reaction (RT-PCR) we were able to identify a novel deep intronic variant, NM_015909.3(NBAS):c.2423+404G&gt;C, leading to the inclusion of a pseudo-exon. This mechanism has not been described previously in this syndrome. CONCLUSIONS: This study highlights the utility of analyzing NGS data in conjunction with investigating complementary DNA (cDNA) using techniques such as RT-PCR for detection of variants that otherwise would be likely to be missed in common NGS bioinformatic analysis pipelines. Combining these approaches, particularly when the phenotype match is strong, could lead to an increase in the diagnostic yield in acute liver failure and thus aid in targeted treatment, accurate genetic counseling and restoration of reproductive confidence.</style></abstract><notes><style face="normal" font="default" size="100%">Rius, Rocio&#xD;Riley, Lisa G&#xD;Guo, Yiran&#xD;Menezes, Minal&#xD;Compton, Alison G&#xD;Van Bergen, Nicole J&#xD;Gayevskiy, Velimir&#xD;Cowley, Mark J&#xD;Cummings, Beryl B&#xD;Adams, Louisa&#xD;Ellaway, Carolyn&#xD;Thorburn, David R&#xD;Hakonarson, Hakon&#xD;Christodoulou, John&#xD;eng&#xD;Case Reports&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Mol Genet Metab. 2019 Jan;126(1):77-82. doi: 10.1016/j.ymgme.2018.12.002. Epub 2018 Dec 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30558828</style></url></related-urls><pdf-urls><url>internal-pdf://3829176414/Rius-2019.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ymgme.2018.12.002</style></electronic-resource-num></record></records></xml>